Cephalon Inc. (CEPH) reported strong third-quarter earnings of $1.62 per share that easily surpassed the Zacks Consensus Estimate of $1.42 per share and the year ago earnings of $1.18. Revenues increased 10.2% to $549 million, consisting of $535 million in product sales and $14.2 million in other revenues. Higher revenues and lower costs contributed to the robust results.   Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $291.9 million (up 7%) and $83.1 million (up 58%), respectively. Oncology drug Treanda continued to perform well, with sales coming in at $54.5 million. Additional data presentations on Treanda should help drive sales, especially in the indolent non-Hodgkin’s lymphoma (NHL) market.   Cephalon reported $20.9 million in sales of its follow-on sleep franchise product, Nuvigil, which was launched on June 1, 2009. The company reported that Nuvigil gained a 19% share ...

We are initiating coverage of Oxygen Biotherapeutics, Inc. (OXBO) with an ‘Outperform’ rating. Despite what has been a tumultuous past for the company and a abysmal fate for competitors attempting to develop similar products, the potential upside that Oxycyte offers is too significant to ignore.  Does Oxycyte do what management says it does? (Key Efficacy Question) In theory, Oxycyte has the potential to be a wonder drug -- a sort of WD-40 of medicine. Preclinical data suggests that Oxycyte has astounding potential for the treatment of traumatic brain injury (TBI), decompression sickness, carbon monoxide poisoning, sickle cell crisis, organ preservation and as a neuroprotectant in patients with myocardial infarction or stroke. The effects in TBI were clearly evident in the phase I program conducted by Oxygen Bio in 2006. Initial phase II data from STOP-TBI will become available in 2010. However, data from small ...

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Cephalon, Inc. (CEPH) recently received priority review from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for Nuvigil. The company had filed the sNDA in June 2009, seeking to expand Nuvigil’s label as a treatment for improving wakefulness in patients with excessive sleepiness associated with jet lag disorder due to eastbound travel. Priority review status means that a response from the agency will be out in six months instead of the usual 10-12 month review period. As such, a response from the FDA should be out by December 29, 2009. Nuvigil is Cephalon’s follow-on sleep franchise product which received FDA approval in June 2007 for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), narcolepsy and shift work sleep disorder (SWSD). Cephalon launched Nuvigil in June 2009 and is promoting the product aggressively. The company has ...

Yesterday, Oxygen Biotherapeutics, Inc. announced that the company has received approval from Israel’s Ministry of Health to begin a Phase II-b clinical trial for use of Oxycyte(R), a perfluorocarbon therapeutic oxygen carrier, in traumatic brain injuries. With four centers in Israel, the clinical trial is part of a larger study that also includes seven trial centers in Switzerland.

The company has named the study “Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury” or “STOP TBI.” The dose escalation trial aims to discover the lowest possible dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg. Dose escalation will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

Chris stern, company chairman and CEO, stated, “This

...

Performance Health Technologies, Inc. is a New Jersey based company that develops and markets performance evaluation and rehabilitation products that monitor and guide exercise and give real-time motivational feedback. With an array of talented members on the Performance team, the young company’s products have been tested, accepted, and endorsed by leaders in the medical, rehabilitation and athletic communities.

While Performance Health has branched out into many markets, the company has begun to make its mark in three distinct fields: Rehabilitation, Fitness and Home Care. Within each of these markets, Performance has taken a lead role in the business world and has positioned itself to become a force in the marketplace.

In the rehabilitation field, Performance has gained national recognition for their breakout product SportsRAC. SportsRac is designed to help rehabilitate professional baseball players from rotator cuff surgery. SportsRac is

...

Oxygen Biotherapeutics, Inc. is a pharmaceutical company dedicated to oxygen therapies and continuous substrate monitoring. For those unfamiliar with oxygen therapies, it refers to products that mimic human blood’s oxygen transport ability. Oxygen therapeutics are in turn broken into two categories based on transport mechanism: perfluorocarbon based, and hemoglobin based.

The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and an implantable glucose sensor. Oxycyte®, once commercialized, may help patients recover from traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.

Yesterday the company announced that the animal studies conducted using rats given different doses of Oxycyte showed improved brain cognitive ability after brain trauma. The researchers found that injured animals treated with a dose of Oxycyte had significant improvement in ability to learn. The ability to learn and perform complex tasks (a maze)

...

Performance Health Technologies, Inc. (PFMH.OB) is a company that has started a revolutionary wave on how people are recovering from neurological disorders involving the joints. Over the last nine years, the company’s development team has created MotionTrack™, which synergizes the latest software and medical technology onto its proprietary platform. The Core:TX® system is able to provide patients with immediate feedback by turning rehabilitation therapy into a wireless, game-like challenge.

The Core:TX® not only makes the repetitive rehabilitation movements more enjoyable, the system is also able to provide health professionals with info on patients’ unique body makeup. Some patients have tremendous strength but lack flexibility in their movements, while others have a wide range of motion with little strength. By using the Core:TX®, healthcare professional and physical therapists are now able to customize clients’ therapy based upon recordable measurements. Performance professional and at-home products

...

Oxygen Biotherapeutics Inc. (OTCBB: OXBO) engages in marketing innovative pharmaceuticals and medical devices to monitor respiration in patients suffering from or associated with respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.

The company today announced it will submit an amended test protocol to the U.S. Food and Drug Administration, as well as in Canada, to cover the dose escalation studies of the company’s therapeutic oxygen carrier Oxycyte. The company plans on recruiting 40 traumatic brain injury (TBI) patients in each country to test the safety and efficacy of Oxycyte.

“Personally, I think that the extensive data we will collect in the dose escalation studies should be more than needed for proof-of-concept in both safety and efficacy. The advantage is that we should have the data we need much earlier, after each cohort of 10, rather than after 200 patients as it was previously planned. Another important

...

For the past nine years, Performance Health Technology, Inc. has been developing and marketing evaluation and rehabilitation products that monitor and guide exercise and give real-time motivational feedback. While the company prides itself on helping others teach and treat themselves, Performance Health has formed a new partnership that may take healthcare to the next level.

Performance Health announced a partnership with the Minnesota based company Logic Product Development to design a next generation Core: TX® rehabilitation device.

The Core:TX® is a computer-based program that utilizes wireless motion-sensing technology designed for neuromuscular re-education. This is a technique used by rehabilitation therapists to restore normal movement in patients with neurological conditions, such as stroke and traumatic brain injury.

Performance CEO Robert Prunetti is very excited about the partnership. Prnuetti said, “We are excited by Logic’s mission to help its clients design, develop, and deliver better

...